Trump’s MMR Split Puts US Vaccine Makers In Commercial Limbo
Trump’s push to replace combination vaccination with individual shots could now test whether manufacturers see enough certainty to invest in a new product mix.
Scrip - August 13, 2026

Sangamo’s Bankruptcy Sale Splits Gene Therapy Assets Between Lilly, PTC
A distressed auction handed PTC Therapeutics a Fabry therapy months from filing and Eli Lilly several gene-editing and delivery platforms.
Scrip - August 13, 2026

BioVie Maps Out Parkinson’s Phase III After Endpoint Row And Stock Rout
BioVie is advancing bezisterim into a Parkinson's Phase III trial after an endpoint controversy wiped more than half its market value following the Phase II readout.
Scrip - August 13, 2026

Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy
Seven deaths and other adverse events associated with use of the Prader Willi syndrome drug have led to calls for more caution over its use, but a rival’s Phase III failure has left it more in command the market.
Scrip - August 13, 2026

Zealand Cashes In On Rusfertide With Royalty Pact
Deal Snapshot: The Danish drugmaker is selling its economic interests in the blood cancer drug to Royalty for $100m to focus on its core metabolic health business.
Scrip - August 13, 2026

Chinese AI-Driven Biotechs Make Splash With Financing Deals, Again
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
Scrip - August 13, 2026

Low Demand Causes TÜV NORD Scandinavia Bankruptcy Just 7 Months After Purchase
Swedish notified body will shut its doors after a financial review found that disproportionate investment would be required to make it profitable.
Medtech Insight - August 13, 2026

Industry Groups Urge India To Enact Standalone Medical Devices Act, Say 30-Plus Fixes Ignored
Eleven Indian industry and patient groups have written to the health minister demanding a standalone Medical Devices Act, saying the 2026 draft bill recycles rejected proposals and applies pharma-style criminalization to engineering products.
Medtech Insight - August 13, 2026

Five Barriers Blocking Asia-Pacific’s Medtech Ascent — And The Playbooks To Overcome Them
Regulatory approval is only the beginning. Reimbursement, talent, IP, funding and infrastructure gaps are preventing Asia-Pacific medtechs from scaling globally. Here’s what founders, MNCs and governments must do differently.
Medtech Insight - August 13, 2026

NAW’s Expanding EPR Legal Offensive Sows Uncertainty For State Packaging Programs
The National Association of Wholesaler-Distributors has filed its broadest constitutional challenge yet to a state EPR law, suing Colorado while awaiting a potentially precedent-setting ruling in its Oregon case that could impact EPR programs nationwide.
HBW Insight - August 12, 2026

Methyl-Life Founder Turned From Health Crisis To Personalized Nutrients Targeting Genetic Factors
Jamie Hope discovered her chronic illness with symptoms including crippling fatigue, debilitating headaches, extreme muscle stiffness and pain, belly pain and low mood, was linked to genetic factors requiring specialized nutrients.
HBW Insight - August 12, 2026

Reckitt’s Mucinex 12HR Cold & Fever Approved On Additional Evidence Supporting Naproxen Dosing
Reckitt launching Mucinex 12HR Cold & Fever Multi-Symptom following FDA approval in December 2025 and after it responded to complete response letter with additional evidence supporting combining naproxen with guaifenesin and dextromethorphan used in Mucinex DM.
HBW Insight - August 12, 2026

Axing Self-Affirmed GRAS Pathway Without Notification Spurs Resource, Authority Questions
Demand on FDA resources and one-year deadline following effective date for notifications for ingredients already available self-GRAS but not notified could be more than FDA bargains for. Proposed rule also could order more than FDA has authority to do.
HBW Insight - August 12, 2026

Aeon Buys Time For Botox Biosimilar As Key FDA Feedback Looms
Aeon has extended its cash runway into 2027 and regained NYSE American compliance as it awaits FDA feedback that will shape the clinical requirements for its proposed Botox biosimilar ABP-450.
Generics Bulletin - August 13, 2026

Mabwell Secures Global Deals For Eylea Biosimilar
Mabwell has secured four new commercialization deals for its aflibercept biosimilar across the GCC and ASEAN regions, while its wholly owned subsidiary T-mab passed a second PIC/S GMP inspection for its denosumab biosimilars.
Generics Bulletin - August 13, 2026

ANI Targets 15-Plus Annual Generics Launches To Sustain Rare Disease Push
ANI’s generics business kept growing and accelerated its launch cadence in Q2, reinforcing its role as a cash generator for the company’s rare disease expansion even as Cortrophin guidance was trimmed.
Generics Bulletin - August 13, 2026

ICH Finalizes Guideline To Harmonize Additional-Strength Biowaivers
ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.
Generics Bulletin - August 13, 2026

Landmark FDA Clearance Moves Aurisco Closer To Leqvio Supply
Aurisco has cleared an FDA pre-approval inspection for inclisiran sodium at its Yangzhou site, strengthening its position as a US-facing supplier of generic oligonucleotide APIs while also advancing a broader complex API and finished-dose strategy.
Generics Bulletin - August 13, 2026

Eric Green’s Vision For Trace Neuroscience
Eric Green, CEO and co-founder of Trace Neuroscience, shared the progress his company has made — and the potential he sees — since its founding in 2024.
In Vivo - August 12, 2026

Sanofi’s Bilingual Scientist: A Workforce Rebuilt Around AI
The company says it has cut research cycle times in half and wants to double its molecule output. Its new CEO is cutting late-stage assets and raising the bar for what advances – which makes the workforce it is building the bet that must pay off.
In Vivo - August 12, 2026